Abselion

Established in 2018 by CEO Ruizhi Wang and based in Cambridge, UK, Abselion, formerly known as HexagonFab, provides automated advanced protein quantification technology, facilitating precise analysis of biologics for research and development in pharmaceuticals and biotechnology. In December 2024, Abselion raised GBP 6. 6 million in Series A funding led by investor M Ventures, with participation from investor R42. Other investors include BioProcess360 Partners, Untitled Ventures, and BGF Ventures.

Abselion's core product offering is the Amperia benchtop instrument, which simplifies the quantification of biologics, including antibodies, adeno-associated viruses (AAVs), and other proteins from crude samples. The device utilises redox electrochemical detection (RED), converting protein binding into an electrical signal, eliminating the need for optical components, and enabling a compact, low-maintenance design. The Amperia is engineered for sensitivity and specificity, allowing for effective quantification with minimal sample preparation required. Amperia enhances laboratory workflows and is compatible with standard 96-well plates to facilitate up to four parallel measurements during various stages of biologics research, including discovery and process development.

The company targets a global client base that includes research institutions, biotechnology firms, and pharmaceutical companies, focusing on markets in North America, Europe, and Asia. The company will use the December 2024 funding to commercialise its system and expand its capabilities for protein quantification in bioprocessing.